Visit of Debiopharm Research & Manufacturing SA in Martigny
The EPFL Alumni Vaud-Valais Chapter invites you to visit DEbiopharm Research & Manufacturing SA in Martigny on Thursday, April 23rd, 2025.
Registration will open as soon as the invitation email is sent out.
👉 Registration : required (event limited to 50 people) :
📅 Date : Thursday, April 23rd, 2026
📍 Venue : Rue du Levant 146, 1920 Martigny
⏳ Timing: 18h00-21h00
💲Participation : The event is free of charge for all contributing EPFL Alumni, 20 CHF for non-contributors
Program
18h00 : Welcome to Debiopharm building
18h15 : Presentation of Debiopharm Research & Manufacturing SA by Cédric Sager, CEO
19h00 : Group tour of the laboratories and production area
20h00 : Networking cocktail
21h00 : End of the event
If the event is full, click “Interested” to be placed on the waiting list in case of cancellations.
⚠️ If you need to cancel your participation, please do so promptly on the EPFL Alumni platform to allow others to participate. Thank you!
Logistical details will be sent to participants a few days before the event. Don't forget to unsubscribe on the platform if you are unable to attend.
Debiopharm Research & Manufacturing SA
Debiopharm Research & Manufacturing S.A. is an independent biopharmaceutical company based in Martigny, Switzerland, committed to developing tomorrow's treatments to cure cancer and infectious diseases and improve patients' quality of life.
The company is a global leader in the field of injectable sustained-release technologies based on polylactic-co-glycolic acid (PLGA). This technology has been used for one of our flagship products, Decapeptyl®, an injectable controlled-release formulation of triptorelin, a gonadotropin-releasing hormone (GnRH) agonist analog. (GnRH). This mode of administration developed by Debiopharm Research & Manufacturing is based on the “encapsulation” of the active substance in a PLGA polymer to allow its gradual dissolution and distribution in the patient's body. The company has successfully produced sustained-release (SR) formulations with a duration of 1 month, 3 months, and 6 months, thereby improving patient comfort.
It has a production unit for its sustained-release formulations as well as research, development, and industrial transposition sectors for new products and/or technologies (www.debiopharm.com ).
For the committee EPFL Alumni, Chapter VD-VS
Jürg Furrer, President
Michèle Berner, Secretary, Responsable of the Valais activities
© Photo credits: KEYSTONE
Alumni
| Ticket | Sales end date | Left | Price |
|---|
